Deal Reinforces HighVista’s Expanding Secondary Market Capabilities

BOSTON, Sept. 23, 2025 — HighVista Strategies LLC (“HighVista” or the “Firm”), an employee-owned specialty alternative asset manager, has closed a bespoke secondary transaction to provide liquidity for investors in mature venture capital funds. This deal, involving seven HighVista funds with over $425 million in net asset value, utilized various structures, including traditional sales and hybrid continuation vehicles, which helped to provide investors added flexibility to sell or retain their interests. The process, managed with Evercore, attracted over 40 potential bidders, reflecting HighVista’s strategic approach in today’s evolving market where companies are remaining private for longer.

Kirsten Morin, Co-Head of Venture Capital at HighVista, highlighted the Firm’s focus on active portfolio management, stating, “We’re proud to deliver an innovative liquidity solution that accelerates realized returns for our investors, showcasing our team’s ability to navigate complex market dynamics. We appreciate the continued trust our investors place in us and remain laser focused on delivering value through every market cycle.”

Building on a recent lower middle market buyout transaction that proactively accelerated liquidity for clients, this venture transaction extends HighVista’s engagement in the secondary market, where the Firm has long utilized secondaries both to generate liquidity and to identify differentiated opportunities across strategies.

“The secondary market has become a central part of private markets, and HighVista is well-positioned to capitalize on it from both sides,” said Raphael Schorr, Deputy Chief Investment Officer at HighVista Strategies. “It’s a powerful tool for generating liquidity in a market where traditional exits have slowed, and it offers potential for attractive, risk-adjusted returns. Our integrated platform gives us a distinct analytical edge, enabling us to structure sophisticated solutions for our own funds and act as a strategic capital partner for transactions sourced through our network.” 

About HighVista
HighVista Strategies LLC is an employee-owned alternative asset manager that brings investors alpha opportunities in structurally inefficient markets. Based in Boston and founded in 2004, HighVista manages $10.5 billion of capital on behalf of sophisticated investors globally. Our culture combines inquisitive thinking with rigorous discipline, enabling us to identify and execute on opportunities with high conviction. HighVista is a partner for investors looking beyond the standard playbook for differentiated ideas that can amplify returns. HighVista’s investment strategies span private markets, including private credit, lower middle market private equity, and early-stage venture capital; public markets, including biotechnology equities and hedged public markets strategies; as well as multi-strategy alternatives.

Media Contact
Prosek Partners for HighVista
[email protected]

Important Disclosure

The views and options expressed here reflect the judgments and opinions of HighVista Strategies LLC at the time of this publication, do not purport to be complete, and are subject to change. No obligation to update or otherwise revise such views and opinions is being assumed. This publication does not constitute, and should not be construed as, an offer of advisory services, securities or other financial instruments, a solicitation of an offer to buy any security or other financial instrument, or a recommendation to buy, hold or sell a security or other financial instruments in any jurisdiction.  Information provided herein is based upon data and analysis that is believed to be accurate as of the time of writing, but no representation or warranty is made herein. THIS PUBLICATION CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE U.S. FEDERAL SECURITIES LAWS.  FORWARD-LOOKING STATEMENTS ARE THOSE THAT PREDICT OR DESCRIBE FUTURE EVENTS OR TRENDS AND THAT DO NOT RELATE SOLELY TO HISTORICAL MATTERS.  FOR EXAMPLE, FORWARD-LOOKING STATEMENTS MAY PREDICT FUTURE ECONOMIC PERFORMANCE, DESCRIBE PLANS AND OBJECTIVES OF MANAGEMENT FOR FUTURE OPERATIONS, PERFORMANCE AND RISK AND MAKE PROJECTIONS OF REVENUE, INVESTMENT RETURNS, RISK CALCULATIONS OR OTHER FINANCIAL ITEMS.  FORWARD-LOOKING STATEMENTS CAN GENERALLY BE IDENTIFIED AS STATEMENTS CONTAINING THE WORDS “WILL,” “BELIEVE,” “EXPECT,” “ANTICIPATE,” “INTEND,” “CONTEMPLATE,” “ESTIMATE,” “ASSUME,” “TARGET” OR OTHER SIMILAR EXPRESSIONS.  SUCH FORWARD-LOOKING STATEMENTS ARE INHERENTLY UNCERTAIN, BECAUSE THE MATTERS THEY DESCRIBE ARE SUBJECT TO KNOWN (AND UNKNOWN) RISKS, UNCERTAINTIES AND OTHER UNPREDICTABLE FACTORS, MANY OF WHICH ARE BEYOND CONTROL.  NO REPRESENTATIONS OR WARRANTIES ARE MADE AS TO THE ACCURACY OF SUCH FORWARD-LOOKING STATEMENTS. 

SOURCE HighVista Strategies LLC

Investment accelerates the development of the open-source Obot MCP Gateway and Nanobot MCP Agent Framework

SAN FRANCISCO, Sept. 23, 2025 — Obot AI, an open-source software company building secure, enterprise-ready platforms for the emerging Model Context Protocol (MCP) standard, today announced a $35 million seed funding round.

The round was co-led by Mayfield Fund and Nexus Venture Partners.

The new capital will support Obot as it expands the development of its open-source projects, including the Obot MCP Gateway and Nanobot MCP Agent Framework, and grows its engineering and product teams. Launched in August 2025, the Obot MCP Gateway offers a unified, open-source control plane that enables IT teams to manage and secure MCP servers and build MCP-enabled AI solutions.

“The MCP standard is reshaping how organizations adopt AI,” said Sheng Liang, CEO of Obot AI. “But without a standard platform, companies struggle with fragmentation, governance, and integration challenges. Obot AI is building an Enterprise MCP Platform so every organization can safely adopt, scale, and innovate with AI assistants.”

As more enterprises integrate AI tools and capabilities, IT leaders are grappling with the challenge of providing access while maintaining control and ensuring safety. The Obot MCP Gateway addresses this gap by giving organizations a clear path to adopt new technology. Nanobot introduces a full agent framework built around MCP and MCP-UI, paving the way for rich AI agents capable of delivering a dynamic UI directly within the chat interface.

“Enterprises urgently need a way to unlock the value of AI assistants while ensuring governance, security, and trust,” said Ursheet Parikh, Partner at Mayfield Fund. “Obot AIs MCP Platform is the missing piece of enterprise infrastructure, and we’re thrilled to support Sheng and his team as they bring this vision to life.”

“The Obot team has a proven track record of building critical open-source infrastructure platforms for developers and enterprises,” said Jishnu Bhattacharjee, Managing Director at Nexus Venture Partners. “We believe Obot AI will become the standard foundation for how enterprises integrate AI tools and agents.”

Obot’s founding team previously created Rancher Labs (acquired by SUSE) and Cloud.com (acquired by Citrix), two companies that redefined how enterprises adopt open-source platforms at scale. With Obot.ai, the team focuses on doing the same for AI technologies.

To learn more about Obot or the recent Obot MCP Gateway and Nanobot projects launch, visit https://obot.ai.

About Obot.ai
Obot AI is building an open-source Enterprise MCP Gateway to accelerate the adoption of AI technology in the Enterprise. By providing a standard, open-source foundation for building, running, and scaling MCP servers, Obot AI enables enterprises to move from experimentation to real-world adoption with governance, security, and trust. Obot AI was founded by the team behind Rancher Labs (acquired by SUSE) and Cloud.com (acquired by Citrix). For more information, visit Obot.ai or explore our projects on GitHub.

Media Contacts

Taylor Sullivan           
PANBlast
[email protected]

Connie Lin
Obot AI
[email protected]

SOURCE Obot.ai

The oversubscribed round, led by Wellington Management and General Catalyst, will be used to enhance and scale the Company’s Enterprise Health Platform, and transform health benefit management and administration for employers and plans

Rebrand signals the Company’s evolution as a full-spectrum benefits technology partner for employers and health plans, including its next-generation pharmacy benefit manager (PBM)

NEW YORK, Sept. 23, 2025 — Capital Rx, Inc., the enterprise health technology company and benefit administrator, today announced a $400 million investment, including a $252 million Series F funding round along with additional investments into the Company’s securities, scheduled to close in early October, led by Wellington Management and General Catalyst, with participation from Generation Investment Management, Growth Equity at Goldman Sachs Alternatives, 9Yards Capital, B Capital, Edison Partners, Prime Health Investments, and Transformation Capital, among others. Concurrent with the investment, the Company is rebranding as Judi Health™ to better reflect its roots and broadened capabilities as a full-service health benefits technology company helping employers design and manage health benefit programs that meet their unique needs.

The transition to Judi Health and supportive funding marks a pivotal moment in addressing the fundamental inefficiencies of health benefits administration and the rising cost of care in the U.S., which is projected to jump almost 9% in 2026, marking the sharpest increase in over a decade. Despite this drastic increase in cost, Americans’ health outcomes are getting worse. Patients struggle to understand the true cost of their healthcare visits, prescriptions, and procedures, and this lack of transparency often results in delayed or deferred care for what could be a life-saving treatment. 

“Judi Health is rewriting the playbook for how benefits are delivered,” said Joshua Sommerfeld, Healthcare Sector Lead at Wellington Management. “By combining a transparent PBM model with a scalable, AI-powered platform, they’re building the infrastructure for the next generation of health benefit administration. Employers are demanding better solutions, and Judi Health is uniquely positioned to meet that moment.”

The oversubscribed financing round will help the company expand its PBM operations and fuel the deployment of Judi Health’s Enterprise Health Platform (EHP) to bring a full suite of employer-facing health benefits services that meet evolving customer needs with clarity and flexibility through brands including:

• Capital Rx, which will continue to operate as an industry-leading, transparent PBM, recognized for its flat-fee-based, aligned pricing model, member-centric service approach, and operational efficiency.
• Judi Health™, the company’s full-service health benefit management platform that integrates unified care navigation through Judi Care™ for pharmacy, medical, vision, and dental benefits with unified claim administration and related workflows, allowing employers and plan members to easily manage all their health benefits through a single solution.
• Judi^®, short for adjudication, is the company’s purpose-built EHP. Judi^® provides administrative workflows for millions of plan members across Fortune 500 companies, the largest unions in America, leading health systems, Medicare and Medicaid plans, and top academic institutions.

“With Judi, Capital Rx has built a platform that not only meets the needs of today’s employers and health plans, but is engineered to adapt and grow with them,” said Holly Maloney, Managing Director at General Catalyst. “We believe their leadership in transparent PBM and their vision to unify pharmacy and medical benefits represent a transformative shift in healthcare administration, and we look forward to deepening our relationship.”

Founded in late 2017 by Chief Executive Officer AJ Loiacono and Chief Technology Officer Ryan Kelly, Judi Health has earned national recognition for its technology advancements and aligned pricing model in pharmacy benefit management, a foundation it will maintain and build upon. With more than 4 million employer PBM members and over 54 million health plan lives already contracted to run on the Judi platform, developed from the ground up, the company is entering the broader health benefits market as an innovator and leader with deep experience, proven infrastructure, and a robust customer base.

“We believe that Judi Health is building the foundational infrastructure for a more transparent U.S. healthcare system,” said Jonah Surkes, Director at Generation Investment Management. “For as long as health benefits remain obscured by misaligned incentives and legacy technology, patients will continue to suffer, whether at pharmacy counters or hospital beds. Today, as Judi Health expands from pharmacy into unified claims and full benefit administration, we see it reaching a critical inflection point — and we are pleased to partner with them at this moment of acceleration.”

“We’ve seen unprecedented demand for Capital Rx, our transparent pharmacy benefit offering, and with the introduction of Judi Health, we are able to help our customers also administrate medical, dental, and vision benefits on a single platform,” said Loiacono. “The U.S. healthcare ecosystem has far too many ‘rent seekers’ inflating costs, hiding fees, and delivering substandard care due to a combination of misalignment and a reliance on antiquated technology. Judi Health is not just the promise of better care; it is the technology that powers the future of U.S. healthcare.”

About Judi Health
Judi Health is a health technology company providing a comprehensive suite of solutions for employers and health plans, including:

• Capital Rx: a public benefit corporation delivering full-service pharmacy benefit management (PBM) solutions to self-insured employers
• Judi Health™: full-service health benefit management for employers, TPAs, and health plans
• Judi^®: a single, scalable SaaS solution that health plans can utilize to manage all their claim workflows

Through these solutions, Judi Health is executing on its mission to give our country the infrastructure it needs for the healthcare we deserve. To learn more, visit www.judi.health.

Media Contacts
Michael Passanante, SVP, Marketing & Communications
Justin Venneri, Senior Director, Communications
[email protected] 

‍Alex Jenkins, 120/80 MKTG
[email protected]

SOURCE Capital Rx

WAGENINGEN, Netherlands and DINTELOORD, Netherlands, Sept. 23, 2025 — Dutch food-tech scale-up Revyve has raised nearly €24 million in Series B financing, bringing its total capital raised to more than €40 million. The investment will accelerate the company’s commercial rollout of functional yeast proteins designed to replace eggs and additives in mainstream food categories.

The Series B round was co-led by ABN AMRO Sustainable Impact Fund and Invest-NL with regional support from Brabantse Ontwikkelings Maatschappij (BOM) and strategic investments by Lallemand Bio-Ingredients’ Swiss affiliate Danstar Ferment and Grey Silo Ventures (CVC of Cereal Docks Group). Existing investors Oost NL and Royal Cosun doubled down on their commitment. This diverse investor base combines institutional, public, and strategic expertise to back Revyve’s mission of reshaping and transforming the alternative protein space by powering next-gen clean-label solution.

Clean-label solutions for a changing food landscape

Revyve produces highly functional yeast proteins that mimic the performance of eggs in food categories such as bakery, sauces, alternative meat and plant-based dairy. Unlike many substitutes, Revyve’s ingredients are natural, more sustainable, and price competitive, helping manufacturers respond to three pressing industry challenges:

• Rising egg costs: Volatile pricing is driving demand for affordable and price stable alternatives.
• Scrutiny of ultra-processed foods: Brands are under pressure to eliminate additives while keeping functionality.
• Sustainability: Major retailers and food manufacturers are demanding cuts to CO₂ footprints across the supply chain.

“Food manufacturers are cutting back on eggs to offset increasing prices and reach sustainability targets, but replicating their unique functionality is crucial to maintaining the texture and mouthfeel consumers are used to. This is exactly where our Yeast Proteins come in, providing an affordable and clean label solution for egg replacement or egg reduction” said Cedric Verstraeten, CEO of Revyve. “This funding round marks a tipping point for us: allowing us to modularly scale production and branch out to more food categories and serve our sustainable solutions to larger customers worldwide”

Scaling production in the Netherlands

In 2024, Revyve commissioned its first-of-a-kind (FOAK) production facility in Dinteloord, the Netherlands. Already running at capacity for several customers, the site has proven the company’s ability to produce and sell industrial volumes. With this new investment, Revyve will expand output to over 1,600 tons per year, ensuring reliable supply for global accounts.

Verstraeten adds: “Strong regional support from both the Wageningen and Brabant ecosystems has enabled us to scale to industrial levels in record time.  With a stellar team and strong investor backing, we have an incredibly solid foundation for global expansion.”

Strong investor backing

The Series B round marks strong confidence in Revyve’s proprietary technology and market potential.

• “We are excited to partner with Revyve as they pioneer pressing sustainable alternatives to traditional egg ingredients. Their solution addresses a critical need in the food transition: scalable ingredients with a low environmental footprint and compelling economics for food manufacturers. We believe this combination of commercial viability and measurable sustainable benefits makes Revyve uniquely positioned to grow into a global leader. We look forward to supporting their journey.” said Hanna Zwietering, ABN AMRO SIF Senior Investment Manager.
• Lisette Kersting-van der Boog, Senior Investment Manager of Invest-NL adds: “With their functional egg-replacement ingredients, Revyve can play a major role in accelerating the global protein transition and fostering circular solutions that reduce pressure on land, water and animals. We are proud to invest in this Dutch company, which strengthens the country’s innovative power with a pioneering technology that has the potential to transform food production worldwide.”
• Furthermore, the plans of Revyve fit perfectly in the BOM’s ambition to grow Brabant into ‘the Scale-Up Plant of Europe‘: “Revyve’s plans align seamlessly with our mission to position Brabant as the Scale-Up Plant of Europe. Their breakthrough technology not only contributes to a more sustainable food system but also exemplifies the kind of bold innovation we aim to foster in the region. We’re proud to support Revyve in scaling their impact from Brabant to the world,” added Ingrid Nieweg, Investment Manager at BOM.”
• Lallemand Bio-Ingredients and Grey Silo Ventures (CVC of Cereal Docks Group) complete Revyve’s Series B round, bringing a wealth of knowledge and synergies in yeast innovation and agri-food expertise.

Looking ahead

With industrial production in full swing, Revyve is already serving customers across Europe, UK, USA, Canada, Mexico and Australia. Building on this momentum, the company will showcase its latest applications and partnerships this autumn at two major industry tradeshows: Anuga (4-8 October, Cologne, Hall 01.2 | Stand D028g-E029g) and Food ingredients Europe (2-4 December, Paris, Stand #73J23).

About Revyve

Revyve, is a purpose-driven food-tech company committed to creating a more sustainable food system. The team of scientists and food industry experts at Revyve share a common vision of enhancing the sensory experience of food through incredible texture. The company arose from Wageningen University & Research (WUR) in the Netherlands, where its founding scientists discovered the potential of yeast to mimic the functionality of eggs. Revyve’s ingredients introduce authentic textures that help replace animal proteins and “clean up” product labels.
www.revyve.bio

About ABN AMRO Sustainable Impact Fund

The ABN AMRO Sustainable Impact Fund is one of the largest private impact funds in the Netherlands and invests in companies that have a positive impact on climate. With a commitment of EUR 500m, funded and managed exclusively by ABN AMRO, we invest through direct equity investments in key transition sectors and focus on the energy transition, the built environment and sustainable consumption.

ABN AMRO Sustainable Impact Fund – ABN AMRO  

About Invest-NL

Invest-NL is the National Promotional Institution of the Netherlands, committed to driving a sustainable and innovative future. We accelerate and finance major societal transitions in the fields of Agrifood, Biobased & Circular Economy, Deep Tech, Energy, and Life Sciences & Health. We remove barriers, mobilise capital, and help develop emerging sectors. Through capital, expertise, and new financial instruments, we invest in tomorrow’s solutions.

www.invest-nl.nl

About Brabantse Ontwikkelingsmaatschappij (BOM)

The Brabant Development Agency (BOM) works together with entrepreneurs to create a future-proof Brabant economy. We share knowledge, develop networks, and provide capital to innovative Brabant companies and sustainable energy projects. We also encourage forward-looking international companies to settle in Brabant and assist companies already based in Brabant to extend their reach abroad. 

http://www.bom.nl

About Grey Silo Ventures

Grey Silo Ventures is the Corporate Venture Capital arm of Cereal Docks Group, dedicated to investing in non-animal-based ingredients and breakthrough technologies in food-tech and ag-tech. With deep roots in plant-based processing, Grey Silo Ventures supports innovation in fermentation, green proteins, cellular agriculture, and functional ingredients.

www.greysiloventures.com

About Lallemand Bio Ingredients

Lallemand Bio-Ingredients is business unit of Lallemand Inc which is a privately-owned business, headquartered in Canada, with over 6,000 employees across 50 countries and 58 production sites worldwide. Lallemand is a global leader in microbial solutions, combining deep scientific expertise with a century-long commitment to innovation and sustainability. Lallemand Bio Ingredients researches, develops, produces and markets food ingredients and flavours made from yeast fermentations at ten production plants located across North America and Europe which produce ingredients including inactive yeast, yeast extracts & autolysates that support the sustainability and natural/clean label status of food products.

http://www.bio-lallemand.com/

For press inquiries, please contact:

Photo – https://mma.prnewswire.com/media/2778025/Revyve_Funding.jpg

SOURCE Revyve

The new automaker proves market differentiation and capital-efficient business model with strategic backing from top investors

SAN CARLOS, Calif., Sept. 23, 2025 — TELO Trucks, maker of the first electric mini truck built for U.S. cities, today announced its oversubscribed $20M Series A funding. This funding round was led by legendary designer Yves Behar, and Marc Tarpenning co-founder of Tesla and Venture Partner of Spero Ventures. Additional investment came from TO VC, E12 Ventures, Neo, Marc Benioff, Uncorrelated Ventures, Nova Threshold, MCJ, and others.

TELO Trucks stands out in the market with a new category of trucks that meets a critical need for functionality across both consumer and fleet audiences. The TELO MT1 delivers the capabilities of a full-size crew cab work truck in the footprint of a 2-door MINI Cooper.

Yves Behar, co-founder of TELO Trucks said: 
“I have great confidence in the TELO team as we build a future-proof vision for mobility. The MT1 proves that innovation can deliver smarter design, greater practicality, and uncompromised capability, shaping how we’ll all move tomorrow.”

Marc Tarpenning, Venture Partner at Spero Ventures said: 
“TELO has the vision, product, capital efficiency, and manufacturing strategy to make the next great transportation company.”

This round follows TELO’s $6M strategic Seed round, led by Neo, and their previous $2M Pre-Seed, led by GoAhead Ventures.

Capital Efficiency

TELO has demonstrated a first-of-its-kind effort in capital efficiency. With only $8M raised over the past three years, TELO launched two fully realized pre-production prototypes that have already earned critical acclaim from the automotive media. This overtakes other automakers who have required in excess of $50M to achieve the same milestone, making TELO the most capital efficient automaker ever.

Joshua Phitoussi, Managing Partner at TO VC said:
“Disciplined scale-up is the name of the game in auto manufacturing. Many companies have made the fatal mistake of scaling up too fast, with too few proof points of product-market fit. TELO, on the other hand, has a liquid and well understood bill-of-materials, and CAPEX-light manufacturing model that leans on blue-chip partners, and 12,000 reservations that get the company well past profitability. This team has shown that they can execute with scarce resources. We’re excited to see what they can do now with strong funding and long-term partners.”

With this new tranche of capital, TELO intends to reach production readiness and pass all federal requirements to get the TELO MT1 on the road.

Strong Market Demand

With over 12,000 pre-orders, representing $600M+, TELO has struck a chord with American consumers. TELO builds right-sized trucks that buck the trend for super-sized, impractical and inefficient alternatives currently available on the market. At just 152 inches in length, the MT1 has the same truck bed length as the Toyota Tacoma and the capability of towing 6,600lb.

Uncompromising Utility

The TELO MT1 all-electric mini truck is over 5 feet shorter than the most popular mid-sized trucks, and two-feet shorter than the 1980s “small trucks” of the past. The world’s most efficient EV pickup, the TELO MT1, delivers:

• Seating for 5 adults
• A 5-foot bed that extends to 8 feet with a folding mid-partition
• Once extended, the bed has space to fit plywood flat on the floor (not over wheel wells)
• All-wheel drive
• Up to 350 miles of range
• Exceptional navigability for high-density towns and cities

Compact in size, the TELO MT1 sets a new standard for what a truck can be.

For more information about TELO, or to pre-order a TELO Truck for only $152 — the length in inches of the vehicle — please visit www.telotrucks.com.

About TELO Trucks
Co-founded by CEO Jason Marks,  CTO Forrest North, and CCO Yves Béhar, with design contributions from fuseproject, TELO Trucks is shrinking the mobility footprint. Its signature TELO Truck, launched in June 2023, combines the bed capacity of a standard pickup and the comfort of a crew cabin in a dramatically compact 152-inch vehicle. With over 12,000 pre-orders since launch, TELO represents a new era of capital-efficient EV companies.

Media Contact
Hannah Dudley
TELO Trucks Communications
[email protected]

Press Kit – TELO Trucks
TELO Trucks LinkedIn
TELO Trucks YouTube Channel

SOURCE Telo Trucks

Landmark investment will accelerate access to cannabis-based healthcare as the UK market approaches a £1bn valuation, positioning Mamedica to support up to 100,000 patients.

NEW YORK, Sept. 23, 2025 — Mamedica, the UK’s leading and most-trusted provider of cannabis-based prescription medicines, today announced a £4.5 million funding round led by Casa Verde, the US-based cannabis-focused venture capital firm.

Casa Verde has backed major cannabis companies including Dutchie, Metrc and Leaflink in the United States, and holds European positions in Cansativa and Sanity Group. The new capital will be used to scale Mamedica’s operations by optimising its in-house supply chain for efficiency and continuity of care, expanding access through a wider clinical network, advancing its proprietary digital healthcare platform with enhanced automation and compliance capabilities, and driving education around the integration of medical cannabis into mainstream healthcare.

Launched in 2022 by CEO and founder Jon Robson, Mamedica provides specialist treatment for chronic and neurological conditions including pain, anxiety, ADHD and depression. Its digital model enables remote consultations with specialist clinicians, with medication delivered nationwide by secure next-day courier. Since inception, Mamedica has treated over 10,000 patients, with approximately 7,500 actively under care and around 10% month-on-month growth in initial consultations. The company recorded 1,250% patient growth in 2023 and 154% in 2024 and expects to double patient numbers annually as the UK medical cannabis industry approaches £1bn in annual sales by the end of 2028.

“We’re excited to partner with Mamedica as the UK cannabis market enters a period of rapid growth,” said Karan Wadhera, Managing Partner at Casa Verde. “Mamedica’s digital-first, patient-centric model sets the standard for care in the UK and offers a blueprint for broader European expansion.”

“This funding marks a pivotal milestone in Mamedica’s mission to transform patient care in the UK,” said Jon Robson, CEO and founder of Mamedica. “The backing of Casa Verde and our private investors validates our approach and enables us to accelerate access to high-quality, regulated treatment.”

About Mamedica

Mamedica is a digital healthcare platform providing UK patients with access to cannabis-based prescription medicines across pain, psychiatry, neurology, palliative care and cancer. Following a secure video consultation, medication is dispensed and delivered nationwide via next-day courier. Founded in 2022, Mamedica prioritises patient care, safety and satisfaction through proprietary technology, specialist clinicians, experienced pharmacists and dedicated support staff.

SOURCE Mamedica

LONDON, Sept. 23, 2025 — Dalton^Tx, a UK-based technology company, today announces its exit from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster.

AI offers pharma a unique opportunity to discover medicines more effectively and efficiently. However, building adaptive AI platforms requires years of investment in software engineering, coupled with deep understanding of the science and technology. Dalton^Tx solves this with a disease- and technology-agnostic adaptive platform that plugs directly into pharma, biotech, and CRO workflows, giving teams instant access to AI-enabled discovery instead of spending years developing these capabilities in-house.

Dalton^Tx is built by scientists for scientists, going beyond predictive modelling to power the full discovery process — from raw data and model training to molecular design, synthesis, and decision-making. Dalton^Tx isn’t just predictive — it’s adaptive, a reasoning engine that learns from every scientist, model, and experiment to continuously improve outcomes.

Born from decades of real-world experience, Dalton^Tx was co-founded by Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE. Together, the team combines drug discovery, machine learning, and software engineering expertise, having built pioneering AI discovery platforms at AstraZeneca and Exscientia and bringing world-leading academic research from the University of Oxford.

‘AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities,’ said Dr Garry Pairaudeau, Co-Founder of Dalton^Tx. ‘Dalton^Tx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability.’

Its platform is purpose-built for both small molecules and biologics, making it uniquely suited to support the most complex R&D pipelines. Furthermore, Dalton^Tx enables collaborative intelligence: scientists can interact with the system, combining their expertise with an engine that iterates and learns, combining human insight and machine learning work together.

‘At Dalton^Tx, we’re generating biological and chemical insight that was previously out of reach,’ said Professor Charlotte Deane MBE, Co-Founder of Dalton^Tx and Professor of Structural Bioinformatics at the University of Oxford. ‘By combining cutting-edge machine learning with deep drug discovery expertise, we are creating technology that learns with every experiment and helps scientists turn ideas into impact.’

With the seed funding from redalpine, IQ Capital Partners, and Seedcamp, and support from Oxford University Innovation, Dalton^Tx will redefine how technology can transform drug discovery.

‘Dalton^Tx is poised to become the intelligence backbone of drug discovery, providing scientific reasoning capabilities and deep integration into real drug discovery workflows. Led by a highly impressive team of industry experts, we believe the Dalton^Tx platform will soon be indispensable for every R&D organization across pharma, biotech, and CROs.” said Marc Moesser, Investment Manager at redalpine.

‘We are excited to back Dalton^Tx, a company poised to set a new standard in R&D execution. By combining world-class science with cutting-edge AI, the Dalton^Tx team is building the adaptive infrastructure that modern drug discovery needs,’ said Mason Sinclair, Principal, IQ Capital.

‘What impressed us most about Dalton^Tx is the strength and depth of the founding team. Their unique combination of drug discovery, machine learning, and software engineering expertise positions them to lead the next generation of AI in pharma. We’re proud to back a team with the vision and execution capability to transform how medicines are discovered,’ added Tom Wilson, Partner, Seedcamp.

Based in the heart of London’s tech and life sciences hub at King’s Cross, Dalton^Tx is positioned at the intersection of engineering, AI, and drug discovery. For more information, visit www.daltontx.com.

About Dalton^Tx

Dalton^Tx is redefining how technology powers drug discovery creating the intelligence engine behind tomorrow’s medicines. Our adaptive AI platform provides pharma, biotech, and CROs with the intelligence backbone that modern R&D can’t move forward without transforming the economics, timelines, and outcomes of discovery. Purpose-built for both small molecules and biologics, Dalton^Tx goes beyond predictive modelling to deliver a self-learning system that integrates seamlessly into scientific workflows and gets smarter with every experiment. Founded on research at the University of Oxford and built by experts in software engineering, machine learning, and drug discovery, Dalton^Tx combines world-class science and technology to help teams design, optimise, and deliver breakthrough medicines, faster. Find out more at www.daltontx.com.

About redalpine

redalpine is the pan-European venture capital firm that empowers GameChangers. Founded in Zurich in 2006, with offices in Berlin, London, and a presence in San Francisco, redalpine brings together financial investment, operational expertise, and a vast international network to help ambitious entrepreneurs transform their vision into a reality. redalpine has over $1bn in assets under management and has backed some of Europe’s most disruptive software and science companies, including N26, Taxfix, Mistral, Klarna, Proxima Fusion, 9fin, and Aktiia. With a multi-stage investment approach, redalpine invests Europe– wide and counts over 100 companies in its portfolio. Find out more at www.redalpine.com

About Seedcamp

Seedcamp partners with Europe’s most exceptional tech founders from Day One. Across their company-building journeys, founders and their teams get access to an unparalleled network, unfiltered advice, and unwavering support.

With almost two decades at the heart of Europe’s tech ecosystem, Seedcamp has earned a reputation for identifying and nurturing the continent’s most promising entrepreneurs with the grit and vision to reshape the future. The Seedcamp Nation now stands at 500+ companies strong and includes publicly listed UiPath and Wise, unicorns Revolut, Synthesia, Sorare, Pleo, wefox, and viz.ai, and a stable of fast-growing businesses across various sectors, such as Sylvera, Lindus Health, Yonder, 9fin and Maze. Find out more at www.seedcamp.com.

About IQ Capital

IQ Capital is a dedicated European deep tech venture capital firm, built on the conviction that frontier technology will underpin the next generation of globally significant companies. We back founders leveraging scientific breakthroughs to build enduring global businesses. We have invested in over 100 of Europe’s most ambitious deep tech teams across six funds since 2005. Find out more at www.iqcapital.vc.

About Oxford University Innovation

Oxford University Innovation (OUI) is the commercialisation arm of the University of Oxford. It works with researchers to create and develop intellectual property from the university’s world-leading research, licensing these innovations to companies and enabling the creation of spin-out businesses. OUI is dedicated to translating groundbreaking academic research into real-world applications that benefit society. Find out more at www.innovation.ox.ac.uk.

SOURCE DaltonTx

Vertical Harvest’s new flagship farm in Westbrook, Maine, demonstrates scale and efficiency: producing the equivalent of 250 acres of traditional farmland on just half an acre, using 95% less water, with the lowest energy consumption per pound of food. With partners Elevated Signals and Siemens advanced digital systems, Vertical Harvest built a replicable, scalable platform for sustainable food production in the Controlled Environment Agriculture (CEA) space.

“Traditional agriculture is at a breaking point,” said Supreet Manchanda, Founding Partner at Raiven Capital. “Vertical Harvest is reinventing not only how we grow food, but where and by whom. Their farms represent scalable infrastructure for the future, and we see powerful applications of such Climatech solutions across the Middle East and beyond.”

Without AI, CEA is labor and energy heavy making unit economics very shaky. AI shifts CEA closer to viable Climatech where resource use becomes highly efficient, margins improve radically, and scalability rises. Raiven treats AI + CEA as a bundle, as inseparable as in autonomous vehicles or drug discovery.

More than a technology story, Vertical Harvest embeds inclusive employment into their operating model. By creating tailored careers for underrepresented workers, including people with disabilities, the company turns high-tech farming into an engine of social mobility.

“Our farms don’t just grow food. They grow futures,” said Nona Yehia, CEO and Co-Founder of Vertical Harvest. “We are proving agriculture can be cutting-edge and fundamentally human-centered.”

“In much of the world, food security is national security,” added Paul Dugsin, Founding Partner at Raiven Capital. “Vertical Harvest is not just transforming agriculture; it is driving cultural and financial change by strengthening economies while building resilience.”

With Raiven Capital’s Dubai based innovation hub and global reach, Vertical Harvest is positioned to expand its model, delivering food sovereignty, economic inclusion, and climate resilience in smart cities worldwide.

About Vertical Harvest
Vertical Harvest designs, builds, and operates vertical farms, fusing controlled environment agriculture with inclusive employment and proprietary AI systems. Learn more at verticalharvestfarms.com.

About Raiven Capital
Raiven Capital is a global multi-fund venture platform investing in AI, IoT and Climatech. With hubs in Silicon Valley, Toronto and Dubai, Raiven backs bold founders reinventing industries.  Learn more at raivencapital.com.

SOURCE Raiven Capital

Already transforming litigation workflows at HSF Kramer, Goodwin Procter, and Addleshaw Goddard, the legal AI platform now flags contradictions live in depositions and hearings; since its pre-seed in 2024, the company has 20x its ARR and expanded its global partnership with Clifford Chance, among others

LONDON, Sept. 23, 2025 — wexler.ai, the AI platform for complex litigation, today announced a $5.3 million seed round led by Pear VC, with participation from Seedcamp, The LegalTech Fund, and pre-seed lead investors Myriad Venture Partners. The funding comes as the company launches Wexler Real-Time, a groundbreaking real-time legal fact-checking feature as part of its fact intelligence platform, already used by top global firms to build chronologies, query vast case materials, and surface key inconsistencies. The new capability flags false or inconsistent testimony as it’s spoken in depositions and hearings. The company also announced new global law firm customers including HSF Kramer, Goodwin Procter, and Addleshaw Goddard.

Since its pre-seed round in 2024, wexler.ai has grown its ARR by 20x and reduced manual review by at least 75%, helping leading law firms and corporate legal teams establish facts faster and with greater accuracy. Long-standing customer Clifford Chance has also embedded wexler.ai across its dispute resolution practice, and Burges Salmon has also adopted the platform to enhance its legal workflows.

“We’re replacing slow, manual, and error-prone litigation review with a system that thinks like a litigator but operates at machine scale and speed,” said Gregory Mostyn, co-founder and CEO of wexler.ai. “With our newest release, litigators can not only build a winning case strategy by mastering the evidence, but challenge inaccuracies as they happen in proceedings.”

“At Pear, we love to partner with highly ambitious founders who are tackling big problems with unique tech,” said Kathleen Estreich, Partner at Pear VC. “Greg and the wexler.ai team are building what’s quickly becoming essential infrastructure for litigation. They combine real-time fact-checking with workflows designed for how lawyers actually win cases, becoming essential for all litigators.”

“In complex disputes, establishing the facts is often challenging and time consuming,” said Charlie Morgan, Partner at HSF Kramer. “The wexler.ai platform is helping our teams do this more quickly and effectively, which in turn helps us improve case strategies, deliver more value and secure the best outcomes for our clients.”

Purpose-Built AI for Litigation
Unlike broad legal AI tools, wexler.ai is designed specifically to think like a litigator. The platform delivers verified, actionable facts with speed and scale, replacing slow and error-prone factual analysis with workflows built for case strategy. For example, tasks like building detailed chronologies that once took days can now be completed in about an hour.

“Litigation is one of the most complex and high-stakes areas of law, and wexler.ai is redefining how lawyers uncover and use facts,” said Tom Wilson, Partner at Seedcamp. “We believe Wexler’s team is building foundational technology that will change the economics of litigation, making legal teams faster, sharper, and ultimately more successful.”

The system extracts, analyzes, and verifies key factual information across massive case datasets, transforming raw data into usable work product. With the ability to process up to 500,000 documents per upload and support multilingual deployments, the technology enables global firms to handle the complexity of modern disputes with precision.

BigLaw Adoption & Multinational Expansion
Growing adoption across top-tier firms highlights the platform’s category-defining role in litigation. From AmLaw 50 leaders in the U.S. to multinational firms in London, and rapid growth in APAC, users report dramatic reductions in review time and stronger confidence in case strategy. Today, more than 70% of wexler.ai users are in the U.S., with rapid growth across the UK, Europe, Canada, and Australia.

“We like the accuracy and litigation-focused design of Wexler – it’s truly a product for litigators,” said David Hobbie, Director, Knowledge & Innovation at Goodwin. “Our lawyers have found it invaluable for early case assessment and thorough fact analysis, including identifying conflicting evidence. We look forward to continuing our partnership with Wexler as adoption spreads and as more fact-related features like the real-time fact checking function are released.”

The new funding will accelerate wexler.ai’s product development; increase the scale of documents to millions per upload, expand the engineering and commercial teams; support wexler.ai’s U.S. launch; and scale multilingual, region‑specific deployments to meet growing demand from top‑tier law firms and corporate teams. Built by privacy and security experts, wexler.ai employs user-specific encryption keys, data masking, and complies with SOC 2 Type II, ISO 27001, GDPR, and AWS Cloud Security standards.

Interested clients can request a demo at https://www.wexler.ai/request-a-demo.

To see more on how Wexler Real-Time works, check out the video here.

About wexler.ai
wexler.ai is transforming complex litigation with advanced AI workflows which find, analyse and verify the key factual information in each case. The platform is trusted by many of the world’s largest law firms and corporate legal teams to identify the winning information that could pivot the trajectory of each litigation. The new funding will be used to expand litigation workflows and accelerate growth across the U.S. and Europe. For more information, visit https://www.wexler.ai/.

Media Contact: [email protected] 

SOURCE wexler.ai